GlobeNewswire Inc.··NaRelay Therapeutics' Zovegalisib Shows Promise in Vascular Anomaly Treatment
Relay Therapeutics reports positive Phase 2 data for zovegalisib in PIK3CA-driven vascular anomalies, with 60% volumetric response and strong safety profile.
RLAYPhase 2 clinical trialbreast cancer